Treace Medical Concepts, Inc. (TMCI) Quick Ratio
- Quick ratio · latest quarter: Value 1.79×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 1.79× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $74.35M ÷ $41.50M ≈ 1.79× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 74.35M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 41.50M USD | Liabilities, Current |
| Cash and equivalents | 12.61M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 33.01M USD | Marketable Securities, Current |
| Customer receivables | 28.73M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 39.54M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $74.35M | $41.50M | $12.61M | $33.01M | $28.73M | $39.54M | 1.79× |
| 2026-03-31 | $82.21M | $34.49M | $9.54M | $42.31M | $30.36M | $36.37M | 2.38× |
| 2025-12-31 | $90.52M | $30.64M | $10.71M | $37.66M | $42.16M | $36.03M | 2.95× |
| 2025-09-30 | $90.38M | $40.91M | $7.69M | $49.73M | $32.96M | $41.42M | 2.21× |
| 2025-06-30 | $99.62M | $41.90M | $8.05M | $61.24M | $30.33M | $42.40M | 2.38× |
| 2025-03-31 | $107.20M | $33.18M | $13.37M | $62.72M | $31.11M | $37.94M | 3.23× |
| 2024-12-31 | $116.48M | $34.92M | $11.35M | $64.33M | $40.80M | $39.26M | 3.34× |
| 2024-09-30 | $106.98M | $38.26M | $12.11M | $70.69M | $24.18M | $43.61M | 2.80× |
| 2024-06-30 | $120.61M | $44.45M | $18.18M | $76.86M | $25.56M | $41.28M | 2.71× |
| 2024-03-31 | $140.09M | $47.05M | $9.33M | $100.67M | $30.08M | $35.86M | 2.98× |
| 2023-12-31 | $161.26M | $45.03M | $12.98M | $110.22M | $38.06M | $29.25M | 3.58× |
| 2023-09-30 | $147.16M | $33.15M | $7.28M | $114.89M | $25.00M | $29.31M | 4.44× |
| 2023-06-30 | $166.71M | $30.02M | $12.04M | $127.44M | $27.23M | $26.10M | 5.55× |
| 2023-03-31 | $196.03M | $23.30M | $29.61M | $141.05M | $25.36M | $22.52M | 8.41× |
| 2022-12-31 | $110.45M | $30.25M | $19.47M | $61.78M | $29.20M | $19.33M | 3.65× |
| 2022-09-30 | (m) | $22.58M | $88.55M | (m) | $18.55M | $16.79M | (m) |
| 2022-06-30 | (m) | $16.64M | $101.53M | (m) | $16.50M | $13.17M | (m) |
| 2022-03-31 | (m) | $15.38M | $98.48M | (m) | $15.99M | $11.11M | (m) |
| 2021-12-31 | (m) | $18.21M | $105.83M | (m) | $18.57M | $10.56M | (m) |
| 2021-09-30 | (m) | $10.72M | $109.46M | (m) | $11.79M | $10.35M | (m) |
| 2021-06-30 | (m) | $9.87M | $119.62M | (m) | $10.05M | $7.64M | (m) |
| 2021-03-31 | (m) | $8.59M | $16.22M | (m) | $10.79M | $7.37M | (m) |
| 2020-12-31 | (m) | $11.60M | $18.08M | (m) | $14.49M | $7.82M | (m) |
| 2020-09-30 | (m) | (m) | $15.40M | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | $10.30M | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | $10.60M | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | (m) | $12.14M | (m) | (m) | (m) | (m) |
| 2018-12-31 | (m) | (m) | $1.28M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |